One of the few success stories in the field of cancer immunotherapy has been the establishment of imiquimod as a standard therapy for the treatment of superficial skin cancers like basal cell carcinoma (BCC), actinic keratosis or preinvasive melanoma (lentigo maligna). The imidazochinoline imiquimod is topically applied to the skin as a 5% cream, and several modes of action against tumors have been suggested. Direct effects on tumor cells can be distinguished from those mediated via the immune system. 1 Imiquimod is capable of directly inducing caspase-mediated apoptosis and inhibiting adenosine signaling in transformed cells in a Toll-like receptor 7 (TLR7)-independent manner. Moreover, imiquimod act as an agonist for TLR7, which is mainly expressed by cells of the immune system, leading to activation and recruitment to the site of imiquimod application. Imiquimodinduced tumor regression is characterized by skin erythema and the presence of an inflammatory infiltrate in and around the tumor, mainly consisting-in humans as well as in 4 In BCC patients receiving imiquimod, skin myeloid DCs and plasmacytoid DCs (pDCs) have been shown to express granzyme B plus perforin and TRAIL, respectively, indicating that imiquimodstimulated DCs might not only play an important role in regulating but also in executing antitumor immune responses by directly killing malignant cells. 5 In an orthotopic mouse model of melanoma, we investigated the mechanisms by which imiquimod recruits immune cells into the skin, with the aim to identify the effector cells that are necessary for tumor killing (Fig. 1) . 6 Since imiquimod is applied topically, we assumed that the first cells responding to imiquimod would be skin-resident cells. By employing bone marrow chimeras we discovered that TLR7 expression by hematopoietic cells, but not other skin cells, is required for the antitumor effect of imiquimod. Mast cells and a few skin-resident pDCs express TLR7 and mast cells have been reported to play a critical role in the induction of adaptive immune responses upon TLR7 ligation. 7 When analyzing imiquimod-treated skins, we found increased amounts of CCL2 and this finding correlated with a higher number of activated mast cells in the dermis (Amberg N., unpublished data). Moreover, mast cells produced CCL2 when stimulated with imiquimod ( Fig. 1) . Since pDCs express CCR2, the receptor for CCL2, it is likely that their recruitment to the skin is induced by CCL2 secreted by mast cells in a TLR7-and MyD88-dependent manner after imiquimod stimulation. Interestingly, CCL2 production by mast cells also relied on Type I IFN signaling (Fig. 1) . Thus, it cannot be formally excluded that resident pDCs themselves produce CCL2. Mice lacking mast cells will have to be studied to clarify this issue.
The key role of pDCs in this setting was confirmed by the finding that pDC depletion in BDCA2-DTR mice completely abolished the antitumor effect of imiquimod. The antitumor effects of imiquimod persisted in Rag2 −/− and athymic mice, de facto excluding T and B cells as putative effector cell candidates. The same held true for NK cells: imiquimod remained active in mice subjected to NK-cell depletion. Thus, pDCs alone seem to be sufficient for tumor clearance as induced by imiquimod. The recruitment of pDCs into tumors was previously considered as a bad prognostic factor, which correlated for less effective. A recent study identified a similar mechanism for imiquimod-treated human pDCs. 10 Our study confirms that only fully matured pDCs are capable of efficiently fighting tumors. Future studies will not only focus on the aforementioned mechanisms of immune-cell recruitment as induced by imiquimod but also on whether the described stimulation of pDCs is a selective feature of the imiquimod-TLR7 signaling axis or whether other ligand-receptor pairs may provide pDCs with comparable killing activities. or indirectly, by upregulating the expression of death-inducing factors by immune cells and/or of the respective receptors by tumor cells. 9 Blocking Type I IFN in in vitro killing assays involving imiquimodstimulated pDCs and melanoma cells did not reduce the lysis of the latter, thus excluding a direct effect of Type I IFN. Instead, autocrine Type I IFN signaling in pDCs increased TRAIL and granzyme B production and secretion. Blocking granzyme B completely abolished the activitiy of imiquimod in vitro, whereas blocking TRAIL or its receptor DR5 was instance with the induction of regulatory T cells (by immature pDCs). 8 Imiquimod, however, induces the TLR7-and MyD88-dependent maturation of pDCs, resulting in the upregulation of CD8 and in the production of Type I IFN, in vitro and in vivo. CD8 and the Type I IFN receptor 1 (IFNAR1) seem to be critical for the antitumor activity of imiquimod since this was abolished by the depletion of CD8α 
